Candel Therapeutics, Inc. CADL Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$54.42M-42.5% | -$38.18M-67.8% | -$22.76M-2.8% | -$22.14M+44.1% | -$39.58M+28.3% | ||
| $712K-11.9% | $808K-9.2% | $890K0.0% | $890K0.0% | $890K-0.7% | ||
| $4.96M+29.8% | $3.82M+1.2% | $3.77M-0.6% | $3.79M-17.3% | $4.58M-13.7% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $1.32M+384% | $272K+247% | ||
| —— | —— | —— | —— | -$27K-104% | ||
| —— | —— | —— | $1.64M+473% | -$440K-88.0% | ||
| $111.5K-37.4% | $178K— | —— | —— | —— | ||
| -$481K+5.5% | -$509K+5.4% | -$538K+0.2% | -$539K-2.5% | -$526K-2.5% | ||
| -$47.73M-24.6% | -$38.31M-14.2% | -$33.56M-12.3% | -$29.89M-9.9% | -$27.2M-0.7% | ||
| $1.26M+114% | $587K+224% | $181K+389% | $37K+208% | $12K-25.0% | ||
| —— | $27K— | —— | —— | —— | ||
| -$1.23M-120% | -$560K-264% | -$154K-316% | -$37K-208% | -$12K+25.0% | ||
| —— | —— | —— | —— | —— | ||
| $155.15M+161% | $59.47M-44.7% | $107.49M-1.5% | $109.16M+16.5% | $93.67M-0.7% | ||
| $102.82M+497% | $17.23M-75.5% | $70.41M-11.1% | $79.23M+19.2% | $66.45M-1.2% | ||
| $2.25M+75.8% | $1.28M+41.6% | $904K-24.5% | $1.2M-20.0% | $1.5M-16.5% | ||
| —— | —— | —— | —— | —— | ||
| $622K+72.8% | $360K+142% | $149K-21.6% | $190K-17.7% | $231K-14.4% | ||
| $712K-11.9% | $808K-9.2% | $890K0.0% | $890K0.0% | $890K-0.7% | ||
| -$481K+5.5% | -$509K+5.4% | -$538K+0.2% | -$539K-2.5% | -$526K-2.5% | ||
| $50K+108% | $24K+140% | $10K+128% | -$36K+18.2% | -$44K+17.0% | ||
| —— | —— | —— | $1.64M+473% | -$440K-88.0% | ||
| $143K+3.6% | $138K+3.8% | $133K+3.1% | $129K+4.9% | $123K+3.4% | ||
| $339K+5.6% | $321K+5.6% | $304K+3.8% | $293K+3.5% | $283K+3.3% | ||
| —— | $47.95M— | —— | —— | —— | ||
| —— | -$11.73M-17.3% | -$10M0.0% | -$10M0.0% | -$10M-9.1% | ||
| $158K+17.0% | $135K— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $93K— | —— | —— | —— | ||
| —— | —— | -$15.89M-21.2% | -$13.1M-321% | $5.93M-71.5% | ||
| $111.5K-37.4% | $178K— | —— | —— | —— | ||
| -$481K+5.5% | -$509K+5.4% | -$538K+0.2% | -$539K-2.5% | -$526K-2.5% | ||
| —— | $2.08M— | —— | —— | —— | ||
| -$48.99M-25.9% | -$38.9M-15.3% | -$33.74M-12.7% | -$29.93M-10.0% | -$27.21M-0.6% | ||
| -$48.99M-25.9% | -$38.9M-15.3% | -$33.74M-12.7% | -$29.93M-10.0% | -$27.21M-0.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Candel Therapeutics, Inc. generate?
- Candel Therapeutics, Inc. (CADL) generated -$47.7M in operating cash flow over the trailing twelve months.
- What is Candel Therapeutics, Inc.'s free cash flow?
- After $1.3M of capital expenditures, Candel Therapeutics, Inc.'s free cash flow was -$49.0M over the trailing twelve months, down 80.0% year over year.
- Where does Candel Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Candel Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
